// App-Quantinova.ai

e22075 : Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).

Researchers

Presenter

  • Fabienne Schochter

Principal Investigators

  • Julia Katharina Neugebauer

  • Thomas Decker

  • Angelika Ober

  • Tanja N. Fehm

  • Klaus Pantel

  • Peter A. Fasching

  • Andreas Schneeweiss

  • Matthias W. Beckmann

  • Wolfgang Janni

  • Brigitte Kathrin Rack

  • Thomas W. P. Friedl

  • Aurelia Pestka

  • Julia Kathrin Jueckstock

  • Bernadette Jaeger

  • Jessica Christine Salmen

  • Philip Gm Hepp

  • Georg Heinrich

  • Oumar Camara

Medical Centers

  • Medical Office of Oncology, Ravensburg, Germany

  • Department of Gynecology and Obstetrics Heinrich-Heine-University Dusseldorf, Duesseldorf, Germany

  • Department of Gynecology and Obstetrics, University of Tuebingen, Tuebingen, Germany

  • St. Vincent Hospital Limburg, Limburg, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • Medical Office of Gynecology, Fuerstenwalde, Germany

  • Department of Gynecology and Obstetrics Ludwig-MaximiliansUniversity, Munich, Germany

  • Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • University of Erlangen-Nuernberg, Erlangen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Fluorouracil

  • Adrucil injection

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00847444

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved